terbutaline sulfate

terbutaline sulfate


Pharmacologic class: Selective beta2-adrenergic receptor agonist

Therapeutic class: Bronchodilator

Pregnancy risk category B


Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors; inhibits release of hypersensitivity mediators, especially from mast cells


Injection: 1 mg/ml

Tablets: 2.5 mg, 5 mg

Indications and dosages

Bronchospasm in reversible obstructive airway disease

Adults and children older than age 12: 0.25 mg subcutaneously, repeated in 15 to 30 minutes p.r.n., up to a maximum of 0.5 mg in 4 hours. Or 2.5 to 5 mg P.O. q 6 hours t.i.d. while awake, up to a maximum of 15 mg/day in adults; 2.5 mg P.O. q 6 hours t.i.d. while awake, up to a maximum of 7.5 mg/day in children.

Dosage adjustment

• Renal impairment

Off-label uses

• Tocolytic in preterm labor


• Hypersensitivity to drug, its components, or sympathomimetic amines


Use cautiously in:
• cardiovascular disorders, hypertension, arrhythmias, hyperthyroidism, diabetes mellitus, seizure disorders, glaucoma
• concurrent use of MAO inhibitors, tricyclic antidepressants, or beta-adrenergic blockers
• elderly patients
• breastfeeding patients.


• Inject subcutaneously into lateral deltoid.

Adverse reactions

CNS: tremors, anxiety, nervousness, insomnia, headache, dizziness, drowsiness, stimulation

CV: palpitations, chest discomfort, tachycardia

GI: nausea, vomiting

Skin: diaphoresis, flushing


Drug-drug. Beta-adrenergic blockers: blockage of bronchodilating effect

MAO inhibitors, tricyclic antidepressants: potentiation of terbutaline's adverse cardiovascular reactions

Other sympathomimetic amines: additive adverse cardiovascular reactions

Patient monitoring

• Monitor vital signs.
• Assess neurologic status.

Patient teaching

• Tell patient he may take with or without food.
• Advise patient or parents to establish effective bedtime routine to minimize insomnia.
• Instruct patient or parents to space doses evenly during waking hours, to avoid taking drug at bedtime.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

terbutaline sulfate

a beta2-adrenergic stimulant.
indications It is prescribed as a bronchodilator in the treatment of asthma, bronchitis, and emphysema and as a uterine relaxant to treat premature labor.
contraindications Cardiac arrhythmias or known hypersensitivity to this drug prohibits its use. Toxicity is increased by monoamine oxidase inhibitors and tricyclic antidepressants, and beta-adrenergic blocker effects are decreased.
adverse effects Among the most serious effects are dizziness and palpitations. Nervousness and tremor are common reactions.


A beta-adrenergic receptor agonist used for patients with COPD.
Asthma, bronchitis, reversible bronchospasm.
Adverse effects
Tremor, nervousness, palpitations, nausea, vomiting.

terbutaline sulfate (terbū´təlēn´),

n brand names: Brethaire, Brethine, Bricanyl;
drug class: selective β2-agonist;
action: relaxes bronchial smooth muscle by direct action on β2-adrenergic receptors;
uses: bronchospasm, asthma prophylaxis, premature labor inhibitor.
References in periodicals archive ?
100 bots ciprofloxacin 200mg 100 vials dextrose 50% 50cc 50 amps diphenhydramine 100 bots dopamine premixed 120 vials hydrocortisone 250mg 20 amps terbutaline sulfate
FDA Citizen Petition Response: Terbutaline Sulfate, Docket No.
ABSTRACT: A woman who was 30 weeks pregnant was given terbutaline sulfate to prevent premature labor contractions.
Terbutaline sulfate was prescribed, and the patient was discharged home.
I was given the drug, terbutaline sulfate (both orally and by injection), as well as betamethasone injections from my 24th week of pregnancy until his birth.
Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA) of Terbutaline Sulfate Tablets 2.
Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Terbutaline Sulfate Injection, USP.
Women pregnant with twins shouldn't be given a month's supply of terbutaline sulfate (Brethine) and told to take one when they have contractions, because there is no evidence that this prolongs pregnancy.
Food and Drug Administration has granted final approval for the Company's ANDA for Terbutaline Sulfate Injection, 1 mg/mL.
Powers, Executive Vice President and Chief Operating Officer, stated, "We are encouraged by the quarter's 2% sequential revenue growth we have achieved despite the impact on our maternity management business caused by confusion resulting from the FDA letter to physicians reiterating that the use of terbutaline sulfate for the management of preterm labor is an 'off- label' use.
The significant year-over-year increase came on the ramp up of sales of Fludrocortisone Acetate Tablets, introduced at the end of the first quarter of 2002, Minocycline Hydrochloride Capsules launched in the third quarter of 2002, Rimantadine Hydrochloride Tablets launched in the fourth quarter of 2002, Terbutaline Sulfate Tablets introduced since July 2001, higher Lipram sales, and lower product returns.
The significant year-over-year increase came on the ramp up of sales of Fludrocortisone Acetate Tablets, introduced at the end of the first quarter of 2002, Minocycline Hydrochloride 50, 75 and 100mg Capsules launched in the third quarter of 2002, as well as other products introduced since July 2001, such as Terbutaline Sulfate Tablets and Methitest(TM) Tablets, and lower product returns.